The Oral Antibiotics Market was valued at $22,468.27 million in 2022 and is estimated to reach $28,819.98 million by 2032, exhibiting a CAGR of 2.5% from 2023 to 2032.
Oral antibiotics are medications that are administered by the mouth and designed to treat bacterial infections. They are ingested as tablets, capsules, or liquids, and are absorbed into the bloodstream through the digestive system. Oral antibiotics work by either killing the bacteria (bactericidal) or inhibiting their growth and reproduction (bacteriostatic). They achieve this by targeting specific bacterial structures or processes essential for their survival, such as inhibiting cell wall synthesis, disrupting protein synthesis, or interfering with DNA replication.
The choice of oral antibiotic is influenced by factors such as the spectrum of activity (the range of bacteria the antibiotic is effective against), its pharmacokinetic properties (absorption, distribution, metabolism, and excretion), the safety profile of drugs, and the susceptibility of the bacteria to the antibiotic. Some common classes of oral antibiotics include penicillin, cephalosporins, macrolides, fluoroquinolones, tetracyclines, and sulfonamides.
The growth of the oral antibiotic market is mainly attributed to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. Bacterial infections, ranging from common respiratory tract infections to more severe infections such as urinary tract infections (UTIs) and skin and soft tissue infections (SSTIs), continue to affect a substantial portion of the population across the globe. For instance, according to an article by Medscape in 2023, urinary tract infections (UTIs) are common in the U.S., with at least 20% of women affected by one UTI in their lifetime. In addition, the growth in population, urbanization, and change in lifestyle factors contribute to the increased prevalence of infectious diseases and thereby driving market growth.
Furthermore, the aging population and the prevalence of chronic diseases also drive the oral antibiotics market. The elderly population and individuals with chronic conditions have a higher risk of developing infections due to weakened immune systems. Thus, increase in prevalence of these conditions drives the demand for oral antibiotics to prevent and treat associated infections.
Moreover, advancements in antibiotic development play a crucial role in driving the oral antibiotics market. Continuous R&D efforts have led to the discovery of new oral antibiotics with improved efficacy, expanded spectrum of activity, and reduced side effects. These advancements meet the unmet medical needs and improve patient outcomes, driving market growth.
However, the oral antibiotic market faces certain restraints that may impede its growth and development. The emergence and spread of antibiotic resistance pose a significant challenge. Over time, bacteria can develop resistance to the antibiotics, making them less effective in treating infections. This necessitates the development of new antibiotics or alternative treatment options, which can be time-consuming and costly. In addition, stringent regulations and guidelines related to antibiotic use and its prescription contribute to the challenges in the development and market availability of antibiotics drugs. This may hinder market growth.
Furthermore, increase in awareness about the importance of timely and appropriate treatment for bacterial infections has led to higher demand for antibiotic medications. Healthcare professionals and public health campaigns emphasizing the appropriate use of antibiotics have contributed to this awareness, thereby boosting the market demand.
The oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides and others. Beta lactam & beta lactamase inhibitors are further segmented into penicillin, cephalosporin and others. On the basis of application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental and others. Community- respiratory tract infections (CARTIS) is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs). On the basis of drug origin, the market is categorized into natural, semisynthetic and synthetic. On the basis of spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and mid/narrow-spectrum antibiotic. On the basis of drug type, the market is divided into branded and generics. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players that operate in the market include Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd, Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited.
Oral antibiotics are medications that are administered by the mouth and designed to treat bacterial infections. They are ingested as tablets, capsules, or liquids, and are absorbed into the bloodstream through the digestive system. Oral antibiotics work by either killing the bacteria (bactericidal) or inhibiting their growth and reproduction (bacteriostatic). They achieve this by targeting specific bacterial structures or processes essential for their survival, such as inhibiting cell wall synthesis, disrupting protein synthesis, or interfering with DNA replication.
The choice of oral antibiotic is influenced by factors such as the spectrum of activity (the range of bacteria the antibiotic is effective against), its pharmacokinetic properties (absorption, distribution, metabolism, and excretion), the safety profile of drugs, and the susceptibility of the bacteria to the antibiotic. Some common classes of oral antibiotics include penicillin, cephalosporins, macrolides, fluoroquinolones, tetracyclines, and sulfonamides.
The growth of the oral antibiotic market is mainly attributed to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. Bacterial infections, ranging from common respiratory tract infections to more severe infections such as urinary tract infections (UTIs) and skin and soft tissue infections (SSTIs), continue to affect a substantial portion of the population across the globe. For instance, according to an article by Medscape in 2023, urinary tract infections (UTIs) are common in the U.S., with at least 20% of women affected by one UTI in their lifetime. In addition, the growth in population, urbanization, and change in lifestyle factors contribute to the increased prevalence of infectious diseases and thereby driving market growth.
Furthermore, the aging population and the prevalence of chronic diseases also drive the oral antibiotics market. The elderly population and individuals with chronic conditions have a higher risk of developing infections due to weakened immune systems. Thus, increase in prevalence of these conditions drives the demand for oral antibiotics to prevent and treat associated infections.
Moreover, advancements in antibiotic development play a crucial role in driving the oral antibiotics market. Continuous R&D efforts have led to the discovery of new oral antibiotics with improved efficacy, expanded spectrum of activity, and reduced side effects. These advancements meet the unmet medical needs and improve patient outcomes, driving market growth.
However, the oral antibiotic market faces certain restraints that may impede its growth and development. The emergence and spread of antibiotic resistance pose a significant challenge. Over time, bacteria can develop resistance to the antibiotics, making them less effective in treating infections. This necessitates the development of new antibiotics or alternative treatment options, which can be time-consuming and costly. In addition, stringent regulations and guidelines related to antibiotic use and its prescription contribute to the challenges in the development and market availability of antibiotics drugs. This may hinder market growth.
Furthermore, increase in awareness about the importance of timely and appropriate treatment for bacterial infections has led to higher demand for antibiotic medications. Healthcare professionals and public health campaigns emphasizing the appropriate use of antibiotics have contributed to this awareness, thereby boosting the market demand.
The oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides and others. Beta lactam & beta lactamase inhibitors are further segmented into penicillin, cephalosporin and others. On the basis of application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental and others. Community- respiratory tract infections (CARTIS) is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs). On the basis of drug origin, the market is categorized into natural, semisynthetic and synthetic. On the basis of spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and mid/narrow-spectrum antibiotic. On the basis of drug type, the market is divided into branded and generics. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players that operate in the market include Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd, Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antibiotics market analysis from 2022 to 2032 to identify the prevailing oral antibiotics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the oral antibiotics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global oral antibiotics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Application
- Community-acquired respiratory tract infections (CARTIs)
- Type
- Upper Respiratory Tract Infections
- Lower Respiratory Tract Infections
- Urinary tract infections (UTIs)
- Dental
- Others
By Class
- Beta Lactam and Beta Lactamase Inhibitors
- Type
- Penicillin
- Cephalosporin
- Others
- Quinolone
- Macrolide
- Others
By Spectrum of Activity
- Broad-spectrum Antibiotic
- Mid/Narrow-spectrum antibiotic
By Drug Origin
- Natural
- Semisynthetic
- Synthetic
By Drug Type
- Branded
- Generic
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Pfizer Inc.
- Alkem Laboratories Ltd.
- Lupin
- Bayer AG
- Teva Pharmaceutical Industries Limited
- Abbott Laboratories
- Novartis AG
- Cipla Ltd
- SUN PHARMACEUTICAL INDUSTRIES LIMITED
- F. Hoffmann-La Roche Ltd.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ORAL ANTIBIOTICS MARKET, BY CLASS
CHAPTER 5: ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY
CHAPTER 6: ORAL ANTIBIOTICS MARKET, BY APPLICATION
CHAPTER 7: ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN
CHAPTER 8: ORAL ANTIBIOTICS MARKET, BY DRUG TYPE
CHAPTER 9: ORAL ANTIBIOTICS MARKET, BY REGION
CHAPTER 10: COMPETITIVE LANDSCAPE
CHAPTER 11: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, the oral antibiotics market was valued at $22.5 billion in 2022, and is estimated to reach $28.8 billion by 2032, growing at a CAGR of 2.5% from 2023 to 2032.The oral antibiotics market is likely to experience a significant growth rate of 2.5% from 2023-2032 owing to increasing market demand of beta lactam & beta lactamase inhibitors segment.
Oral antibiotics are medications that are ingested by the mouth and designed to treat bacterial infections. They are available in various forms such as tablets, capsules, or liquids. Once absorbed into the bloodstream through the digestive system, oral antibiotics target and kill bacteria or inhibit their growth. They are widely used to treat a range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and gastrointestinal infections. Oral antibiotics are prescribed on the basis of type of infection, the specific bacteria involved, and patient factors such as allergies and medical history.
The increasing incidence of infectious diseases is a significant driver of the oral antibiotics market. Infectious diseases caused by bacteria, such as respiratory tract infections, urinary tract infections, and skin infections, continue to affect populations worldwide. For instance, according to an article by National Library of Medicine published in 2021, urinary tract infections (UTIs) are common in the U.S., with an annual incidence of 12% among women and 3% among men. Factors like population growth, urbanization, and international travel contribute to the spread of these diseases. As a result, there is a growing demand for effective treatments like oral antibiotics to combat these infections and prevent complications.
In addition, the aging population is another key driver of the oral antibiotics market. Elderly individuals are more susceptible to infections due to weakened immune systems and the presence of chronic medical conditions. As the global population continues to age, there is a higher demand for healthcare services, including treatments for infections that are more prevalent among the elderly. Oral antibiotics are often preferred in this population due to their convenience and ease of administration, contributing to market growth.
Furthermore, the development of new antibiotics is crucial due to the emergence of antibiotic-resistant bacteria. These resistant strains pose a serious global health threat, making it essential to create novel antibiotics that can effectively treat infections when existing drugs fail. Pharmaceutical companies and research institutions are increasingly focusing on developing innovative antibiotics to address this challenge. For instance, Pfizer Inc., a leading research-based biopharmaceutical company, announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combinations, in treating serious bacterial infections due to gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatment options. This emphasis on R&D drives market growth by providing healthcare professionals with more treatment options to combat both common and drug-resistant infections. Thus, the aforementioned factors are anticipated to drive the market growth.
The oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides and others. Beta lactam & beta lactamase inhibitors are further segmented into penicillin, cephalosporin and others. On the basis of application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental and others. Community- respiratory tract infections (CARTIS) is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTIs). On the basis of drug origin, the market is categorized into natural, semisynthetic and synthetic. On the basis of spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and mid/narrow-spectrum antibiotic. On the basis of drug type, the market is divided into branded and generics.
On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global oral antibiotics market such as Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd, Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited. Key players operating in the market have adopted product launch, agreement and collaboration as their key strategies to expand their product portfolio.
Key Market Insights (Updated)
- On the basis of class, the beta lactam & beta lactamase inhibitors segment dominated the market in terms of revenue in 2022. However, the quinolone segment is anticipated to grow at the fastest CAGR during the forecast period.
- On the basis of application, the Urinary tract infections (UTIs) segment held largest market share in 2022 . However, the Community-acquired respiratory tract infections (CARTIS) segment is anticipated to grow at the fastest CAGR during the forecast period.
- On the basis of spectrum of activity, the Broad-spectrum Antibiotic segment dominated the market in terms of revenue in 2022 and is expected to remain dominant throughout the forecast period.
- On the basis of drug origin, the semisynthetic segment dominated the market in terms of revenue in 2022. However, the synthetic segment is anticipated to grow at the fastest CAGR during the forecast period.
- On the basis of drug type, the branded segment held the largest market share in 2022. However, the generic segment is anticipated to grow at the fastest CAGR during the forecast period.
- On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Pfizer Inc.
- Alkem Laboratories Ltd.
- Lupin
- Bayer AG
- Teva Pharmaceutical Industries Limited
- Abbott Laboratories
- Novartis AG
- Cipla Ltd
- SUN PHARMACEUTICAL INDUSTRIES LIMITED
- F. Hoffmann-La Roche Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
